Thyrocare Technologies Limited announced the outcome of its Board Meeting held on May 07, 2026. The Board recommended a final dividend of ₹7.00 per equity share for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting (AGM). This is in addition to the interim dividend of ₹7.00 per equity share already paid, bringing the total dividend for FY26 to ₹9.33 per equity share. The Board also approved the appointment of M/s. Price Waterhouse Chartered Accountants LLP as the Statutory Auditors for a term of five consecutive years, commencing from the conclusion of the 26th AGM in 2026 until the 31st AGM in 2031, subject to shareholder approval. M/s. Jitender Navneet & Co. were appointed as Cost Auditors for the financial year 2026-27. Key personnel changes were also noted. Mr. Rahul Franklin Guha was re-appointed as Chairman, Managing Director & CEO for a further period of five years, commencing from May 4, 2027, to May 3, 2032. Mr. Uday Patel Kadam and Mr. Gaurav Verma were appointed as Additional Directors (Non-Executive, Non-Independent) effective May 8, 2026. The Board also accepted the resignations of Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah as Non-Executive, Non-Independent Directors, effective May 07, 2026, due to pre-occupations and other commitments. Furthermore, the company approved an investment of up to ₹5.50 crore in equity shares of Think Health Diagnostics Private Limited, its wholly-owned subsidiary, to support its business operations and capital requirements. The Memorandum of Association (MOA) of the company will also be altered to align with the Companies Act, 2013, and broaden its scope within the healthcare and diagnostics ecosystem. The Board Meeting commenced at 03:35 PM and concluded at 05:40 PM.
